Everyone likes to talk about funding for digital health – Y Combinator is doing biotech now! Andreesen Horowitz gets into health tech! Deals and dollars look great in Q1 2014!
It’s not as easy to make cheery slide decks about funding for the rest of the healthcare startup world: pharma, medical devices and bio tech companies. However, the money is still out there for companies working on hard science products.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Our April hangout features three people who specialize in funding healthcare startups. If you need fresh ideas about where to get financial support for your company, tune in to our hangout at noon Eastern on Wednesday. We will speak with people working with early stage and late stage companies as well as an entrepreneur who has found unique ways to fund his cancer vaccine company.
The panel includes:
- Richard Berenson, CEO of Thermalin Diabetes and executive committee member of Mass Medical Angels
- David R. Carter, Principal of Capital Royalty
- Dorit Donoviel, Ph.D. Deputy Chief Scientist at the National Space Biomedical Research Institute
Leading startups and funding them
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Currently Richard Berenson is the CEO of Thermalin Diabetes, but he has been leading organizations and developing practical, break-through strategy for more than 20 years. He has been CEO or COO at 9 startups, including ActivBiotics and HeartLander Surgical. He is also involved with Mass Medical Angels. MA2 is a seed stage investor group exclusively focused on life science and healthcare investments. The group’s mission is to bring more clinical tools to the marketplace, while attaining superior returns for investors.
Royalty and debt deals
David Carter is a principal at Capital Royalty, an investment firm focused on structured financings of commercialized biopharmaceutical products and medical technologies. David joined Capital Royalty in 2003 and has more than 20 years of investment experience. Prior to joining Capital Royalty, he was a partner at Palestra Capital, a New York-based hedge fund, where he focused on risk arbitrage, special situations, and distressed securities.
To space and back again
Dorit Donoviel has more than 20 years of leadership experience as director of R&D overseeing diverse areas of biomedical research from basic to applied science, drug discovery, and technology development. Regularly reports and presents on the entire NSBRI science portfolio as well as the Industry Forum to the NSBRI Board of Directors, External Advisory Council, User Panel, and NASA.
The NSBRI Industry Forum mission is twofold: to commercialize biomedical discoveries made for space, and challenge the private sector to develop space-compatible healthcare solutions.
The Industry Forum focuses on commercialization of NSBRI-funded technologies through activities such as commercialization workshops and market analysis reports. To engage the private sector, in 2011, the Industry Forum Steering Council launched a funding program that recruits small U.S. companies to provide medical innovations that solve the unique challenges of human spaceflight while developing new market opportunities on Earth.